Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2022

View Archived Issues

New DNA-dependent protein kinase inhibitors divulged by Shouyao Holdings

Vasopressin V1A receptor antagonists discovered at Roche

Medshine Discovery identifies SOS1/Gly12Cys mutant GTPase KRAS interaction inhibitors

Betta Pharmaceuticals describes new PTPN11 inhibitors

Merck KGaA, Cancer Research Technology present YAP1/TEAD interaction inhibitors

Akouos presents preclinical data on anti-VEGF AAVAnc80 vector for vestibular schwannoma

ADAM8 drives severity in acute respiratory distress syndrome trough neutrophil migration

Increasing catalase activity reverses estrogen-mediated aging

Aquinnah and Roche collaborate in ALS and neurodegenerative diseases

Alamar and SciNeuro to discover and develop novel therapeutic antibodies for neurological diseases

NTS-104 reduces critical neuroinflammatory signaling in rat embolic stroke model

Persistent Ebolavirus in brain seeds relapses

NIBIOHN and Shionogi announce discovery of novel antiviral antibody for SARS-CoV-2

Memo Therapeutics to advance lead programs

YTHDF1 is involved in renal fibrosis through upregulation of YAP

Financing at Third Harmonic Bio to support development of oral KIT inhibitor THB-001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...